Cancerforskningsfondet Af 1989

Cancerforskiningsfonden Af 1989

Ebbe Ro Slashednne

Vincent Ellis

Charles Pyke

Niels Behrendt

Keld Dano Slashed

Ettore Appella

Wolf-Dieter Schleuning

Eeva-Marjatta Salonen

Michael Ploug

Nils Bruenner

Ann Louring Roldan

Peter Kristensen

Francesco Blasi

Ross W Stephens

Maria Teresa Masucci

Antti Vaheri

Maria Vittoria Cubellis

Hannele Tapiovaara

Gunilla Ho slashedyer-Hansen

Laszlo Patthy

Leif Ro Lund

Lisbeth Birk Mo Slashedller

Jari Pollanen

A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal. Methods for for selecting a substance suitable for inhibiting u-PA/u-PAR interaction, for preventing or counteracting localized proteolytical activity in a mammal, for inhibiting the invasion and/or metastasis comprise the use of the antibodies and of nude mice inoculated with human cancer cells which are known to invade and/or metastasize in mice and having a distinct color, f.x. obtained by means of an enzyme and a chromogenic substrate for the enzyme, the color being different from the cells of the mouse.

Antibodies and their use

Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

Vectors and methods for recombinant production of uPA-binding fragments

Growing community of inventors

Copenhagen, Denmark

Ebbe Ro Slashednne